{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"MGD019"},{"type":"Synonym","name":"dual-affinity retargeting protein MGD019"},{"type":"CodeName","name":"MGD 019"},{"type":"CodeName","name":"MGD-019"},{"type":"Synonym","name":"PD-1 x CTLA4 bispecific DART molecule MGD019"},{"type":"Synonym","name":"PD-1 x CTLA4 DART protein MGD019"},{"type":"Synonym","name":"bispecific DART protein MGD019"},{"type":"Synonym","name":"PD-1 x CTLA4 DART protein MGD019"},{"type":"CASRegistryName","name":"2416595-46-3"},{"type":"CodeName","name":"AEX-1344"},{"type":"CodeName","name":"AEX1344"},{"type":"Synonym","name":"anti-PD-1/anti-CTLA4 DART protein MGD019"},{"type":"Synonym","name":"D-1 x CTLA4 DART protein MGD019"}],"definition":{"html":"A hinge stabilized immunoglobulin G4 (IgG4) tetravalent bispecific antibody-like protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lorigerlimab specifically binds to both PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. Dual blockade of PD1 and CTLA4 pathways provides enhanced activity against PD1+CTLA4+ double positive cells and may increase T-cell activation and proliferation compared to the blockade of either immune checkpoint alone.","text":"A hinge stabilized immunoglobulin G4 (IgG4) tetravalent bispecific antibody-like protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lorigerlimab specifically binds to both PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. Dual blockade of PD1 and CTLA4 pathways provides enhanced activity against PD1+CTLA4+ double positive cells and may increase T-cell activation and proliferation compared to the blockade of either immune checkpoint alone."},"drugInfoSummaryLink":null,"nciConceptId":"C158505","nciConceptName":"Lorigerlimab","termId":797142,"name":"lorigerlimab","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lorigerlimab"}],"links":null}